You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

152 search results for: type 2 inflammation

What Do We Know About <b>Type</b> <b>2</b> <b>Inflammation</b> in COPD?
expert video

What Do We Know About Type 2 Inflammation in COPD?

Pulmonology
Join global expert Dr. Michael Wechsler as he discusses type 2 inflammation in COPD.
View more
The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Atopic Dermatitis
expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

Dermatology
The impact of type 2 inflammation and barrier dysfunction in the pathogenesis of chronic disease in atopic dermatitis.
View more
Effect of <b>Type</b> <b>2</b> <b>Inflammation</b> on Skin Barrier Function in AD​
interactivity

Effect of Type 2 Inflammation on Skin Barrier Function in AD​

Dermatology
Gain insights on how type 2 inflammation affects different aspects of skin barrier function – an interactive educational tool.
View more
Clinical Presentations in AD, PN, and CSU: Role of <b>Type</b> <b>2</b> <b>Inflammation</b>
expert video

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

Dermatology
Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.
View more
The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Skin Barrier Dysfunction in Atopic Dermatitis
expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

Dermatology
Dr. Robert Bissonnette highlights the role of type 2 inflammation in skin barrier dysfunction in atopic dermatitis.
View more
<b>Type</b> <b>2</b> <b>Inflammation</b> Modulates the Neuroimmune Axis in PN
expert video

Type 2 Inflammation Modulates the Neuroimmune Axis in PN

Dermatology
Highlights from the WCD 2023 ADVENT symposium, examining how type 2 inflammation influences the neuroimmune axis in prurigo nodularis.
View more
FeNO as a Biomarker for <b>Type</b> <b>2</b> Asthma
expert video

FeNO as a Biomarker for Type 2 Asthma

Pulmonology
Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.
View more
CRSwNP: A Chronic <b>Type</b> <b>2</b> Inflammatory Disease
expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

Rhinology
Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.
View more
The Cycle of <b>Inflammation</b> in Adult Asthma
interactivity

The Cycle of Inflammation in Adult Asthma

Pulmonology
Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients
View more
Eosinophils as a Biomarker for <b>Type</b> <b>2</b> Asthma
expert video

Eosinophils as a Biomarker for Type 2 Asthma

Pulmonology
Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.
View more
Inside the Hive: <b>Type</b> <b>2</b> Inflammatory Pathways in Chronic Spontaneous Urticaria
expert video

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

Dermatology
Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema
View more
<b>Type</b> <b>2</b> <b>Inflammation</b> in CSU: Emerging Evidence and Implications
expert video

Type 2 Inflammation in CSU: Emerging Evidence and Implications

0
Prof. Ensina describes the main components of CSU pathophysiology and explains how targeted treatments will enable us to learn more about the different pathways of mast cell activation in CSU
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: JapanChange country/region